Holen Sie sich die Stockscreener-App
61.99
3.39%
-2.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$64.13
Offen:
$64.41
24-Stunden-Volumen:
968.35K
Relative Volume:
0.48
Marktkapitalisierung:
$7.57B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-11.79
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-2.44%
1M Leistung:
+2.99%
6M Leistung:
+87.02%
1J Leistung:
+22.69%
1-Tages-Spanne:
$61.80
$65.45
1-Wochen-Bereich:
$61.81
$67.26
52-Wochen-Spanne:
$29.31
$69.33
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
61.89 | 7.84B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $68,730 in shares - Investing.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - sharewise.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - The Motley Fool
Norges Bank Invests $39.12 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by CW Advisors LLC - MarketBeat
Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story (CYTK)? - simplywall.st
Brown Advisory Inc. Has $32.89 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock - MarketBeat
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock By Investing.com - Investing.com South Africa
Insider Sell: Andrew Callos Sells 52,486 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock - Investing.com India
Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - Yahoo Finance
Will Cytokinetics Incorporated (KK3A) stock issue positive guidanceJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Can Cytokinetics Incorporated (KK3A) stock double in coming years2025 Earnings Impact & Weekly Market Pulse Updates - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out - ACCESS Newswire
Is Cytokinetics Incorporated (KK3A) stock overpriced at current multiplesMarket Trend Report & Long-Term Capital Growth Ideas - Newser
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bakersfield.com
Attention Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Cytokinetics, Incorporated $CYTK Shares Sold by Schroder Investment Management Group - MarketBeat
Why analysts recommend Cytokinetics Incorporated (KK3A) stockJuly 2025 Market Mood & Low Drawdown Investment Strategies - Newser
What technical patterns form on Cytokinetics Incorporated (KK3A) stock chartsPortfolio Risk Summary & Short-Term Swing Trade Alerts - Newser
How Cytokinetics Incorporated (KK3A) stock trades under stagflation2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
Cytokinetics, Incorporated $CYTK Position Increased by American Century Companies Inc. - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,200 Shares - MarketBeat
Henderson, Cytokinetics director, sells $559k in stock By Investing.com - Investing.com South Africa
Robert Arthur Harrington Sells 2,150 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics, Incorporated $CYTK Stake Cut by Skandinaviska Enskilda Banken AB publ - MarketBeat
Can Cytokinetics Incorporated (KK3A) stock sustain margin levelsQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - Newser
Cytokinetics, Incorporated $CYTK Shares Sold by Fisher Asset Management LLC - MarketBeat
Will Cytokinetics Incorporated (KK3A) stock draw ESG focused fundsJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
Can Cytokinetics Incorporated (KK3A) stock attract ESG investmentsMarket Risk Report & Long-Term Growth Stock Strategies - Newser
Cytokinetics Insider Sold Shares Worth $559,125, According to a Recent SEC Filing - marketscreener.com
Cytokinetics Executives and Directors Sell Shares - TradingView
Insider Sell Alert: Robert Harrington Sells Shares of Cytokineti - GuruFocus
Cytokinetics (CYTK) director Kaye sells $1.87 million in stock By Investing.com - Investing.com Nigeria
Harrington sells Cytokinetics (CYTK) stock worth $143,620 By Investing.com - Investing.com India
Cytokinetics (CYTK) director Kaye sells $1.87 million in stock - Investing.com
Harrington sells Cytokinetics (CYTK) stock worth $143,620 - Investing.com
Is Cytokinetics Incorporated (KK3A) stock prepared for digital transitionWeekly Trade Review & Verified Chart Pattern Trade Signals - Newser
Rhumbline Advisers Boosts Stock Position in Cytokinetics, Incorporated $CYTK - MarketBeat
What hedge fund moves indicate for Cytokinetics Incorporated (KK3A) stockStop Loss & Verified Stock Trade Ideas - Newser
Capital Fund Management S.A. Acquires 99,117 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Can Cytokinetics Incorporated (KK3A) stock deliver double digit returnsEarnings Trend Report & Growth Focused Stock Pick Reports - Newser
Cytokinetics stock price target raised to $61 from $41 at UBS - Investing.com Nigeria
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):